Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
More Reading from MarketBeat
Hims & Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recovery?Author: Jessica Mitacek. Originally Published: 5/12/2026. 
Key Points
- Hims & Hers shares plunged over 12% in after-hours trading after reporting a Q1 double-miss, with an EPS loss of negative 40 cents versus four cents expected and year-over-year revenue growth of just 3.8%.
- The company is seeing success with its Novo Nordisk partnership, fulfilling over 125,000 Wegovy shipments in Q1, and planning to bolster its global footprint through the acquisition of Eucalyptus.
- Management raised full-year guidance and reiterated ambitious 2030 revenue targets, supported by operating in high-growth telehealth and weight-loss markets that are projected to expand significantly through the end of the decade.
- Special Report: Elon Musk already made me a “wealthy man”
Shares of telehealth provider Hims & Hers Health (NYSE: HIMS) sold off sharply following disappointing Q1 FY2026 financial results, with the stock falling more than 12% in after-hours trading after the company reported on May 11. Expectations for the quarter were high, particularly after the company partnered with Danish multinational pharmaceutical firm Novo Nordisk (NYSE: NVO).
When the SpaceX IPO launches, most retail investors will be locked out. The banks, funds, and insiders get in early - while everyone else waits on the sidelines.
But one small infrastructure supplier - a critical piece Musk can't scale the Colossus network without - is still trading well under institutional radar. A new briefing reveals the name and ticker at no cost. Get the SpaceX infrastructure stock name and ticker here
In March, Novo Nordisk dismissed its patent infringement lawsuit against Hims & Hers Health and entered into a partnership with the company to sell its GLP-1 weight loss drugs Wegovy and Ozempic on the telehealth platform. But that wasn’t enough to prevent the company from posting a double miss in its Q1 report, which marked the company’s fourth miss on both earnings and revenue in the past five quarters. Shares of HIMS are now down more than 50% over the past year, including a loss of nearly 20% year-to-date. The Losing Streak Continues for Hims & Hers HealthOn Monday, the company reported a Q1 earnings per share (EPS) loss of 40 cents, missing analyst expectations by a wide margin. Quarterly revenue came in at $608.10 million, which was also below the consensus estimate of $616.84 million. Concerningly, that figure represents just 3.8% year-over-year revenue growth. The company attributed slower revenue growth and the earnings loss to approximately $33 million in restructuring charges, including roughly $28 million in write-downs tied to the GLP-1 compounding pivot. The earnings report wasn’t all bad news, though. Hims & Hers Health highlighted how its GLP-1 strategy pivot with Novo Nordisk is already bearing fruit. The company fulfilled more than 125,000 Wegovy shipments in Q1 and is on track to add more than 100,000 new weight-loss subscribers per month. Hims & Hers also noted that international expansion is becoming an increasingly important strategic focus. The acquisition of Eucalyptus is expected to be completed in the second half of the year, broadening the company’s global footprint and supporting its 2030 targets of at least $6.5 billion in annual revenue and $1.3 billion in adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA). In his earnings call comments, CEO Andrew Dudum said the company’s growing international reach is becoming a competitive advantage because it expands its total addressable market, increases its value to industry partners, and strengthens platform network effects. Perhaps most importantly for buy-and-hold investors, management raised its full-year guidance for revenue to a range of $2.8 billion to $3 billion and adjusted EBITDA to $275 million to $350 million. Dudum added that “2026 is proving to be a year of accelerating growth, which reinforces our confidence in our ambitious 2030 targets.” Hims & Hers Remains a Growth StoryThe company sits at the intersection of multiple high-growth markets. According to industry consultancy Grand View Research, the global weight loss supplement market, which was valued at $33.14 billion in 2024, is expected to grow at a compound annual growth rate (CAGR) of 14.17% from 2025 to 2030, reaching nearly $72 billion. Grand View Research forecasts that the global telehealth market will grow even faster, with a CAGR of 24.68% from 2025 to 2030. That would lift its value from just over $123 billion in 2024 to more than $455 billion by the end of the forecast period. And while growth in the global hair thinning market is not expected to be as pronounced as it is in the telehealth and weight loss markets, Grand View Research estimates its CAGR at 10.85% from 2025 to 2030. Those projected growth rates bode well for Hims & Hers Health, which is in the process of transitioning from a niche wellness brand into a comprehensive, technology-driven healthcare platform. The company is also expanding into cardiovascular screenings, preventative care, dermatology, and diagnostic partnerships. The Long-Term Prospects Remain PositiveDespite the recent selloff, analyst expectations remain mostly positive. While the stock carries a consensus Hold rating, its average 12-month price target suggests more than 15% potential upside. The high-end price target of $60 implies as much as 100% upside, while the low-end price target of $18 suggests shares of HIMS could see additional losses of around 38%. In the short term, traders should expect more volatility ahead. Current short interest is concerningly high at more than 31%. And while institutional activity slowed dramatically in Q1, sellers outnumbered buyers in Q4 FY2025, with outflows of $861 million easily surpassing inflows of $318 million. At the same time, insider buying has disappeared, while insider selling has totaled nearly $125 million over the past year. That has driven down insider ownership to less than 13%. With a trailing 12-month EPS of 51 cents and a forward price-to-earnings ratio of around 48, Hims & Hers Health’s earnings are expected to grow more than 26% over the next year, from 53 cents per share to 67 cents per share. |
Post a Comment
0Comments